Civitas drug for Parkinson's symptom wins $1M grant

06/19/2013 | American City Business Journals

The Michael J. Fox Foundation for Parkinson's Research awarded Civitas Therapeutics a $1 million grant to support a Phase II study of CVT-301, its lead drug candidate for intermittent debilitating motor fluctuations, which affect many patients with Parkinson's disease. The drug is an inhaled formulation of levodopa, whose approved indications include OFF episodes.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD